Vendor, Malvern, PA
Venatorx Pharmaceuticals Inc.
UEI MBBKNBU5DCC6, CAGE 61SY9
6 awards and $40,477,464 obligated between January 19, 2024 and October 7, 2026, 100% under full and open competition, against 5.5 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $31,255,006 |
| National Institutes of Health | $9,682,676 |
| Defense Threat Reduction Agency | -$460,217 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $31,255,006 |
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $9,663,738 |
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$441,280 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 6 |
| Definitive Contract | 6 |
Hear when Venatorx Pharmaceuticals Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Venatorx Pharmaceuticals Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $9,663,738
- Soonest
- January 31, 2028
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to Office of Assistant Secretary for Preparedness and Response, by dollars.
| Advanced Technology InternationalSummerville, SC | $2,764,576,471 |
| Albert B. Sabin Vaccine Institute, Inc. (The)Washington, DC | $356,898,734 |
| Amgen USA Inc.Thousand Oaks, CA | $345,705,117 |
| Start2 Group, Inc.Cambridge, MA | $227,139,021 |
| Siga Technologies, Inc.New York, NY | $177,835,284 |
| Shionogi Inc.Florham Park, NJ | $156,109,904 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00050Definitive Contract, January 31, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Update Article G.7 Indirect Cost RateNAICS 541714, PSC AN13 | $24,870,405 |
| 75N93020C00016Definitive Contract, July 1, 2024, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | Non Beta-Lactam Inhibitors of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.NAICS 541715, PSC AN12 | $9,663,738 |
| 75A50119C00007Definitive Contract, January 19, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Correct the Period of Performance for Clin0007 to Align with Ipp.NAICS 541714, PSC AN13 | $6,384,601 |
| HHSN272201600029CDefinitive Contract, June 28, 2024, Full and Open Competition, 13 offers | National Institutes of Health NiaidNational Institutes of Health | The Purpose of This Contract Is the Development of a Novel Orally Bioavailable Beta-Lactamase Inhibitor Through Delivery to the Government ONAICS 541711, PSC AN12 | $18,938 |
| 75A50122C00080Definitive Contract, January 24, 2024, Full and Open Competition, 3 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Update Article G.12. Indirect Cost RateNAICS 541714, PSC 6505 | $0 |
| HDTRA117C0070Definitive Contract, February 17, 2026, Full and Open Competition, 3 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | New PBP Inhibitors Impervious to Beta-LactamasesNAICS 541711, PSC AD92 | -$460,217 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN12 Health R&D Services; Health Care Services; Applied Research6505 Drugs and BiologicalsAD92
- Transactions
- 31 across 6 awards